CHICAGO (MedPage Today) -- A study presented here may help unravel the issue of resistance to trastuzumab (Herceptin), a drug that is central to the treatment of HER2-positive breast cancer. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment